Posted in | News | Nanomedicine

Novavax Presents Preclinical and Clinical Findings for its RSV Vaccine

Novavax, the biopharmaceutical company that develops vaccines for a range of diseases, announced that its Senior Vice President and Chief Medical Officer, Gregory Glenn, M.D., presented the findings of the preclinical and clinical study for Novavax’s respiratory syncytial virus (RSV) vaccine development program at the first conference on Modern Vaccines Adjuvants and Delivery Systems at Copenhagen in Denmark.

Dr. Glenn reported that the results of the recently concluded Phase I trial were aligned with the results from the preclinical study carried out on pertinent animal models. This reportedly demonstrates that Novavax’s Fusion (F) protein nanoparticle RSV vaccine is immunogenic, well tolerated and generates functional antibodies capable of neutralizing the virus. RSV is the leading source of pneumonia in adults and the leading source of pneumonia and bronchiolitis in children less than a year old. The development of an RSV vaccine is a challenge and to date, there are no known vaccines for the prevention of RSV infection.

The data from the preclinical and clinical studies provided insight into RSV infection that could greatly aid the synthesis of suitable vaccines. It was found that while subjects with RSV infection showed the presence of anti F-antibodies, specific antigenic sites on the Fusion (F) protein of RSV, labeled as site II showed no presence of the antibodies. Clinical studies revealed that antibodies like palivizumab (trade name Synagis), which is already in use around the world for RSV disease prevention in premature babies, proved to be very effective in RSV prevention. The Novavax RSV F nanoparticle vaccine contains numerous copies of the antigenic site II epitope. Preclinical studies on cotton rats show that the vaccine induced anti-RSV IgG offers protection against the virus. The administration of the vaccine to healthy adults in the Phase I placebo-controlled trial also showed promising results, making the RSV F nanoparticle vaccine a promising candidate for protection against RSV infection.


Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Novavax Inc.. (2019, February 12). Novavax Presents Preclinical and Clinical Findings for its RSV Vaccine. AZoNano. Retrieved on August 10, 2022 from

  • MLA

    Novavax Inc.. "Novavax Presents Preclinical and Clinical Findings for its RSV Vaccine". AZoNano. 10 August 2022. <>.

  • Chicago

    Novavax Inc.. "Novavax Presents Preclinical and Clinical Findings for its RSV Vaccine". AZoNano. (accessed August 10, 2022).

  • Harvard

    Novavax Inc.. 2019. Novavax Presents Preclinical and Clinical Findings for its RSV Vaccine. AZoNano, viewed 10 August 2022,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type